Gabriel Dayan

This project proposes an immunotherapeutic approach for the treatment of acute lymphoblastic leukemia. This is done by transducing self-regenerating hematopoietic stem cells, with an anti-CD22 gene and a promoter to maximize the expressivity of the gene in only cytotoxic immune cells. The gene codes for a receptor targeting CD22: a protein found on the surface of acute lymphoblastic leukemia cells.